Q2 2025 · 13F-HR
Lion Point Capital, LPholdings as filed
Filed 2025-08-14 · accession 0001013594-25-001032
$14.7M
Reported value
19
Positions
2025-06-30
Period end
The Brief · Lion Point Capital, LP · Q2 2025
AI · grounded in 13F
Lion Point Capital, LP established a new position in FENC valued at $1.62M. The fund also initiated new stakes in ARDX for $1.31M and KINIKSA PHARMACEUTICALS INTL for $1.27M. Additional new positions include BBIO at $1.12M and INSM at $1.07M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 31447P100 | FENC | FENNEC PHARMACEUTICALS INC | $1.6M | 11.0% | 195,700 | Common | SOLE |
| 039697107 | ARDX | ARDELYX INC | $1.3M | 8.93% | 335,400 | Common | SOLE |
| G52694109 | KNSA | KINIKSA PHARMACEUTICALS INTL | $1.3M | 8.62% | 45,900 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $1.1M | 7.62% | 26,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $1.1M | 7.28% | 10,650 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $1.1M | 7.26% | 79,000 | Common | SOLE |
| 59935V107 | MIST | MILESTONE PHARMACEUTICALS IN | $1.1M | 7.23% | 548,806 | Common | SOLE |
| G29687103 | AVDL | AVADEL PHARMACEUTICALS PLC | $873,495 | 5.93% | 98,700 | Common | SOLE |
| 471871202 | JSPR | JASPER THERAPEUTICS INC | $813,075 | 5.52% | 146,500 | Common | SOLE |
| 08205P209 | BNTC | BENITEC BIOPHARMA INC | $725,400 | 4.93% | 62,000 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $705,000 | 4.79% | 500,000 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $649,126 | 4.41% | 46,300 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $561,376 | 3.81% | 10,600 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $515,075 | 3.50% | 55,000 | Common | SOLE |
| 75901B107 | RGNX | REGENXBIO INC | $474,128 | 3.22% | 57,750 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $320,297 | 2.17% | 22,700 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $190,624 | 1.29% | 644,000 | Common | SOLE |
| 81750R201 | MCRB | SERES THERAPEUTICS INC | $189,292 | 1.29% | 17,038 | Common | SOLE |
| 44486Q103 | HUMA | HUMACYTE INC | $174,515 | 1.18% | 83,500 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.